Cdk7 Inhibitors

Binds to the ATP-binding pocket of CDKs, including CDK7. Competes with ATP, inhibiting phosphate transfer to target proteins. Disrupts cell cycle progression and transcription, leading to cell cycle arrest and apoptosis. Broad CDK inhibition contributes to its potential as an anticancer agent by blocking proliferation and promoting cell death in various cancer types.

THZ1 is a covalent inhibitor that targets CDK7's ATP-binding site. It inhibits CDK7's kinase activity and impacts transcription by preventing CDK7-mediated phosphorylation of RNA polymerase II.

Roscovitine, also known as CYC202 or seliciclib, is a potent CDK inhibitor that primarily targets CDK2. It competes with ATP for binding to the CDK2 active site, thereby inhibiting its kinase activity. By inhibiting CDK2, Roscovitine blocks cell cycle progression and cell division, leading to cell cycle arrest and apoptosis. This compound has shown potential in cancer treatment due to its ability to regulate cell cycle pathways and inhibit cancer cell proliferation.

DRB is a transcriptional inhibitor that indirectly affects CDK7. It inhibits the transcription elongation process by interfering with the positive transcription elongation factor b (P-TEFb), which includes CDK9 (a kinase subunit of P-TEFb). CDK7 is a component of TFIIH complex, which phosphorylates the C-terminal domain of RNA polymerase II and is essential for transcription initiation.

PHA-767491 is a potent inhibitor of multiple CDKs, including CDK7. It competes with ATP for binding to the CDK active sites, leading to inhibition of their kinase activities. By targeting CDK7, PHA-767491 disrupts the regulation of transcription by hindering the phosphorylation of RNA polymerase II's C-terminal domain. This inhibition affects cell cycle progression and transcriptional processes, ultimately leading to cell cycle arrest and apoptosis.

Blocks ATP binding, preventing CDK7 activation and substrate phosphorylation.

NU 6140 is a selective CDK2 inhibitor. It competes with ATP for binding to the CDK2 active site, preventing the transfer of phosphate groups to target proteins. By inhibiting CDK2, NU 6140 disrupts cell cycle progression, leading to cell cycle arrest and inhibition of cell division. Although it is primarily recognized for its CDK2 inhibition, its potential effects on other CDKs might contribute to its overall impact on cellular processes.

H-8 • 2HCl, also known as N-(2-Aminoethyl)-5-isoquinolinesulfonamide dihydrochloride, is a broad-spectrum protein kinase inhibitor. While its primary target is not CDK7, it can inhibit CDK7 at higher concentrations due to its broad inhibitory activity. H-8 • 2HCl competes with ATP for binding to kinase active sites, leading to the inhibition of phosphorylation processes, including those regulated by CDK7. Its effect on CDK7 is likely due to its non-selective kinase inhibition profile.

CR8, (R)-Isomer is a selective CDK inhibitor, with primary affinity for CDK2. It competes with ATP for binding to the CDK2 active site, blocking phosphorylation events. By inhibiting CDK2, CR8, (R)-Isomer affects cell cycle progression, leading to cell cycle arrest. Its selectivity for CDK2 contributes to its impact on cell cycle control and potential applications in cancer treatment.

Cdk/Crk Inhibitor functions as a potent modulator of Cdk7, exhibiting a unique interaction with the enzyme's active site through a combination of electrostatic and van der Waals forces. This inhibitor disrupts the phosphorylation cascade essential for transcriptional regulation, effectively altering downstream signaling pathways. Its selective affinity results in a distinct kinetic behavior characterized by a prolonged residence time, enhancing its impact on cellular processes. The compound's structural features facilitate targeted disruption of enzyme-substrate complexes, underscoring its role in fine-tuning cellular responses.